Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $5.1B |
| Sales growthchange from the year before | +21.2% |
| Gross marginshare of sales left after the direct cost of what it sells | 92.8% |
| Operating marginshare of sales left after running the business | 29.5% |
| Net marginshare of sales kept as profit | 25.0% |
| Return on invested capitalprofit made on each $100 put into the business | 23.2% |
| Return on equityprofit vs. shareholders' accounting value | 24.9% |
| Change in share countnegative = the company is buying back its shares | -4.7% |
2 insiders sold $7.6M (all under pre-arranged plans) on the open market.
| Mayes Patrick AEVP & Chief Scientific Officer | Sold (plan)Aug 3 | 6,055 shat $120.43 · $729K |
| Cagnoni Pablo JPresident, Global Head of R&D | Sold (plan)Jul 31 | 15,888 shat $119.70 · $1.9M |
| Mayes Patrick AEVP & Chief Scientific Officer | Sold (plan)Jul 31 | 41,899 shat $119.46 · $5.0M |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy